New effective carrier systems for drug delivery in different dosage applications including oral, topical & parenteral
Seamless transition from preclinical to first-in-human trials with EUDRACAP platform technology
Profit after tax (before exceptional items) up 23% to Rs 215 crores
Glenmark's Zita portfolio of medicines have been benefiting around 1.75 million Type 2 diabetic patients annually
This inspection is the fourth major regulatory inspection (after Russia, Canada and Brazil), cleared by this site in the past two years
Glenmark's current portfolio consists of 188 products authorized for distribution in the US
Lupin enters into BTA with Lupin Manufacturing Solutions
He has 37 years of experience in API Intermediaries, Pharma and Chemicals industr
Punit has more than 20 years of experience in the generics and branded pharmaceutical marketplace
He will be responsible for leading all the activities related to the Research & Development (Formulations) Division of the company
Subscribe To Our Newsletter & Stay Updated
